At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 967 enrolled
Drug / intervention
AIN457 150mg +1 moredrug
Likely dose
AIN457 150mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blind, Multicenter Study of Subcutaneous Secukinumab, Assessing Psoriasis Area and Severity Index (PASI) Response and Maintenance of Response in Subjects With Moderate to Severe Chronic Plaque-type Psoriasis on Either a Fixed Dose Regimen or on a Retreatment at Start of Relapse Regimen
In Brief
A Phase 3 clinical trial evaluating AIN457 150mg and AIN457 300mg for Moderate to Severe Plaque-type Psoriasis. Completed, enrolled 967 participants across 131 sites in 16 countries.
Detailed Summary
This study will assess the safety and efficacy of two different doses and two different dose regimens of subcutaneous secukinumab in patients that have moderate to severe, chronic, plaque-type psoriasis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate to Severe Plaque-type Psoriasis
CountriesAustria, Bulgaria, Canada, Czechia, France, Germany, India, Italy, Japan, Poland, Singapore, Slovakia, Switzerland, United Kingdom, United States, Vietnam
Collaborators--
Timeline
Phase 3CompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedAug 2011
Enrollment StartAug 2011
Primary CompletionMay 2013
TodayJul 2026
First PostedAug 1, 2011
Enrollment StartAug 1, 2011
Primary CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 14.9 years ago
Interventions
AIN457 150mgdrug
(1 injection per dose) and placebo to secukinumab 150 mg
AIN457 300mgdrug
secukinumab 150 mg (2 injections per dose)